Clinical trials: Anticoagulants
Venous Thromboembolism (VTE), Cancer
Vortosiran for VTE Prevention
Blood clots remain a serious cause of illness and death. Long-term treatment and prevention of these clots with blood thinners is often limited by bleeding risk, drug interactions, and daily dosing, leading many patients to stop…
- Conditions
- Venous Thromboembolism (VTE), Cancer, Pulmonary Embolism (Diagnosis)
- Trial name
- NCT07850453
- Testing
- Vortosiran
- Where
- 30 sites in Bulgaria, France and 2 more
- Volunteers
- 150 people
- Sponsor
- Ribocure Pharmaceuticals AB
CPB, Oral Anticoagulant Therapy
Study Use of PPSB-SD and VP-VI in Patients With Anticoagulant Therapy and Undergoing Acute CPB Surgery
The purpose of this study was to study the efficacy of PPSB-SD and VP-VI in patients, who received anticoagulant treatment and who had to undergo acute cardiac surgery with a cardiopulmonary bypass (CPB).
- Trial name
- NCT00151853
- Testing
- PPSB-SD
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Prothya Biosolutions
Atrial Fibrillation
Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants
The purpose of this study is to compare the risk of major bleeding event among nonvalvular atrial fibrillation patients treated with warfarin, apixaban, dabigatran and rivaroxaban.
- Trial name
- NCT02754154
- Testing
- Warfarin, Apixaban, Dabigatran
- Volunteers
- 321,182 people
- Sponsor
- Bristol-Myers Squibb
Wound Bleeding
Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B
The goal of this clinical trial is to test if the study drug, BXP154B works to stop bleeding from a minor wound in patients that are on apixaban for anticoagulant therapy.
- Trial name
- NCT06205615
- Testing
- BXP154B, Punch Biopsy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Bio 54, LLC
Non Valvular Atrial Fibrillation
Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation
The investigators will first measure the maximum concentration (after 2 hours of intake) and the residual concentration (just before the next intake) after at least 15 consecutive days of treatment.
- Trial name
- APIXA-Xa (NCT06862726)
- Testing
- Anti Xa dosage, Dosage of PT-INR
- Where
- Tunisia
- Volunteers
- 120 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Atrial Fibrillation
Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter
A study for subjects with atrial fibrillation (AF) or atrial flutter who are diagnosed with left atrial (LA) or left atrial appendage (LAA) thrombus. The study will assign subjects to rivaroxaban for treatment of thrombi.
- Trial name
- X-TRA (NCT01839357)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 31 sites in Bulgaria, France and 5 more
- Volunteers
- 60 people
- Sponsor
- Bayer
Venous Thromboembolism, Arthroplasty, Replacement, Hip
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
The purpose of this study is to evaluate the efficacy and safety of various doses of YM150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip…
- Trial name
- ONYX-3 (NCT00902928)
- Testing
- YM150, enoxaparin
- Where
- 156 sites in United States, Australia and 26 more
- Volunteers
- 1,992 people
- Sponsor
- Astellas Pharma Europe B.V.
Thromboembolism
Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)
The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin Pro re nata (As needed/PRN) to maintain an International Normalised Ratio (INR)…
- Trial name
- RE-COVER II (NCT00680186)
- Testing
- Warfarin, Dabigatran etexilate
- Where
- 220 sites in United States, Australia and 29 more
- Volunteers
- 2,589 people
- Sponsor
- Boehringer Ingelheim
Reversal of Anticoagulant Treatment
Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures
The purpose of this study is to determine whether Octaplex (human prothrombin complex concentrate) can reverse the effects of anticoagulants when compared to the standard treatment of fresh frozen plasma (FFP).
- Trial name
- NCT00618098
- Testing
- Octaplex (human prothrombin complex concentrate), Fresh frozen plasma
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Octapharma
Coronary Artery Disease
Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI
The purpose of this study is to determine if it is feasible and safe to use the REG1 Anticoagulation System instead of unfractionated heparin during percutaneous coronary intervention (PCI) in subjects with coronary artery…
- Trial name
- REVERSAL-PCI (NCT00715455)
- Testing
- REG1, Unfractionated Heparin
- Where
- 6 sites in United States, Argentina
- Volunteers
- 26 people
- Sponsor
- Regado Biosciences, Inc.
Atrial Fibrillation, Stroke
Carotid Artery Implant for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants
This study will assess the safety and performance of the Vine™ Embolic Protection System (embolic filtering device) in atrial fibrillation (AF) patients on top of oral anticoagulants (OAC), and remain at high risk for stroke…
- Trial name
- CAPTURE2 (NCT03892824)
- Testing
- Vine™ Embolic Protection System
- Where
- 17 sites in Belgium, Czechia and 6 more
- Volunteers
- 100 people
- Sponsor
- Javelin Medical
Atrial Fibrillation, Obesity
Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
The overall objective of this analysis is to understand patient characteristics, the use of treatment, and clinical outcomes among obese (overweight) and severely obese patients with non-valvular atrial fibrillation (NVAF) who…
- Conditions
- Atrial Fibrillation, Obesity, Anticoagulants
- Trial name
- NCT04681482
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 107,383 people
- Sponsor
- Pfizer
Non-valvular Atrial Fibrillation (NVAF)
AMPLATZER™ Cardiac Plug Observational Post-Approval Study
The purpose of this study is to observe the safety and effectiveness of the AMPLATZER™ Cardiac Plug (ACP) device in Chinese population indicated for use of AMPLATZER™ Cardiac Plug after its market approval by China FDA (CFDA).
- Trial name
- ACP China (NCT02954237)
- Testing
- AMPLATZER™ Cardiac Plug
- Where
- 6 sites in China
- Volunteers
- 91 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey
This is a national, multi-center, prospective study to evaluate the safety of Edoxaban in patients diagnosed with AF who are currently using Edoxaban for stroke prevention.
- Trial name
- ETAF-TR (NCT04594915)
- Testing
- Edoxaban
- Where
- 45 sites in Turkey (Türkiye)
- Volunteers
- 1,053 people
- Sponsor
- Daiichi Sankyo Turkey, a Daiichi Sankyo Company
Acute Major Bleeding
Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor
This is a multicentre, prospective, randomised, double-blinded, group-sequential, parallel-group, adaptive design, phase 3 study to demonstrate the haemostatic efficacy and safety of four-factor prothrombin complex concentrate…
- Trial name
- NCT04867837
- Testing
- Octaplex
- Where
- 63 sites in United States, Austria and 11 more
- Volunteers
- 100 people
- Sponsor
- Octapharma
Non-Valvular Atrial Fibrillation (NVAF)
A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan
The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.
- Trial name
- NCT05027061
- Where
- Japan
- Volunteers
- 11,776 people
- Sponsor
- Bristol-Myers Squibb
Venous Thrombosis, Deep Vein Thrombosis
Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
This is a multicenter, cohort study evaluating an adapted rivaroxaban dose regimen in patients with acute, proximal deep-vein thrombosis (DVT) or acute pulmonary embolism (PE) who concomitantly use a strong cytochrome P450…
- Trial name
- NCT00786422
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 16 sites in Australia, Austria and 7 more
- Volunteers
- 25 people
- Sponsor
- Bayer
Venous Thromboembolism
Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement
The purpose of this study is to determine if TAK-442, once daily (QD) or twice daily (BID), is as safe and effective as enoxaparin in preventing the development of blood clots after knee replacement surgery.
- Trial name
- NCT00641732
- Testing
- TAK-442, Enoxaparin
- Where
- 64 sites in United States, Canada
- Volunteers
- 1,045 people
- Sponsor
- Takeda
Hemodialysis Complication
UFH is the Most Used Anticoagulant in Hemodialysis, Decreasing the Risk of Clot Formation in the Circuit.
The objective of this study was to verify the clinical non-inferiority of the pharmacodynamic effects and the safety of use of the drug Heptar® manufactured by Eurofarma Laboratory, compared to the drug Liquemine®, manufactured…
- Trial name
- HEPIRC (NCT05148377)
- Testing
- Liquaemin, Heptar
- Volunteers
- 128 people
- Sponsor
- Eurofarma Laboratorios S.A.
Stroke
Use of Direct Oral Anticoagulants in UK
Many people who suffer from irregular heartbeats (atrial fibrillation) which might cause stroke, need to take blood thinners to prevent it.
- Trial name
- NCT03119116
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Dabigatran, Apixaban
- Where
- United Kingdom
- Volunteers
- 31,336 people
- Sponsor
- Bayer